These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 35963941)

  • 1. Molecular determinants of outcomes in relapsed or refractory mantle cell lymphoma treated with ibrutinib or temsirolimus in the MCL3001 (RAY) trial.
    Freeman CL; Pararajalingam P; Jin L; Balasubramanian S; Jiang A; Xu W; Grau M; Zapukhlyak M; Boyle M; Hodkinson B; Schaffer M; Enny C; Deshpande S; Sun S; Vermeulen J; Morin RD; Scott DW; Lenz G
    Leukemia; 2022 Oct; 36(10):2479-2487. PubMed ID: 35963941
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study.
    Dreyling M; Jurczak W; Jerkeman M; Silva RS; Rusconi C; Trneny M; Offner F; Caballero D; Joao C; Witzens-Harig M; Hess G; Bence-Bruckler I; Cho SG; Bothos J; Goldberg JD; Enny C; Traina S; Balasubramanian S; Bandyopadhyay N; Sun S; Vermeulen J; Rizo A; Rule S
    Lancet; 2016 Feb; 387(10020):770-8. PubMed ID: 26673811
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Matching-adjusted Indirect Comparisons of the Efficacy and Safety of Acalabrutinib Versus Other Targeted Therapies in Relapsed/Refractory Mantle Cell Lymphoma.
    Telford C; Kabadi SM; Abhyankar S; Song J; Signorovitch J; Zhao J; Yao Z
    Clin Ther; 2019 Nov; 41(11):2357-2379.e1. PubMed ID: 31699438
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Outcomes in 370 patients with mantle cell lymphoma treated with ibrutinib: a pooled analysis from three open-label studies.
    Rule S; Dreyling M; Goy A; Hess G; Auer R; Kahl B; Cavazos N; Liu B; Yang S; Clow F; Goldberg JD; Beaupre D; Vermeulen J; Wildgust M; Wang M
    Br J Haematol; 2017 Nov; 179(3):430-438. PubMed ID: 28832957
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Health-related quality of life data from a phase 3, international, randomized, open-label, multicenter study in patients with previously treated mantle cell lymphoma treated with ibrutinib versus temsirolimus.
    Hess G; Rule S; Jurczak W; Jerkeman M; Santucci Silva R; Rusconi C; Caballero D; Joao C; Witzens-Harig M; Bence-Bruckler I; Cho SG; Zhou W; Goldberg JD; Trambitas C; Enny C; Vermeulen J; Traina S; Chiou CF; Diels J; Dreyling M
    Leuk Lymphoma; 2017 Dec; 58(12):2824-2832. PubMed ID: 28556689
    [TBL] [Abstract][Full Text] [Related]  

  • 6. IBRORS-MCL study: a Spanish retrospective and observational study of relapsed/refractory mantle-cell lymphoma treated with ibrutinib in routine clinical practice.
    Sancho JM; Marín-Niebla A; Fernández S; Capote FJ; Cañigral C; Grande C; Donato E; Zeberio I; Puerta JM; Rivas A; Pérez-Ceballos E; Vale A; Martín García-Sancho A; Salar A; González-Barca E; Teruel A; Pastoriza C; Conde-Royo D; Sánchez-García J; Barrenetxea C; Arranz R; Hernández-Rivas JÁ; Ramírez MJ; Jiménez A; Rubio-Azpeitia E
    Int J Hematol; 2022 Sep; 116(3):381-392. PubMed ID: 35551632
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predictive factors and outcomes for ibrutinib therapy in relapsed/refractory mantle cell lymphoma-a "real world" study.
    Epperla N; Hamadani M; Cashen AF; Ahn KW; Oak E; Kanate AS; Calzada O; Cohen JB; Farmer L; Ghosh N; Tallarico M; Nabhan C; Costa LJ; Kenkre VP; Hari PN; Fenske TS
    Hematol Oncol; 2017 Dec; 35(4):528-535. PubMed ID: 28066928
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Five year experience in ibrutinib therapy for relapsed and refractory mantle cell lymphoma in real world Russian clinical practice].
    Vorobyev VI; Gemdzhian EG; Fedorova LV; Mikhailova NB; Ilyasov RK; Kaleikina LP; Trubyakova OS; Kaplanov KD; Melnichenko EV; Martynova EV; Yakovleva EP; Li OY; Tarasenko EV; Chumakova EP; Bulieva NB; Nesterova ES; Margolin OV; Zherebtsova VA; Butaev LS; Ptushkin VV
    Ter Arkh; 2021 Jul; 93(7):770-777. PubMed ID: 36286727
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical outcomes for ibrutinib in relapsed or refractory mantle cell lymphoma in real-world experience.
    Jeon YW; Yoon S; Min GJ; Park SS; Park S; Yoon JH; Lee SE; Cho BS; Eom KS; Kim YJ; Kim HJ; Lee S; Min CK; Lee JW; Cho SG
    Cancer Med; 2019 Nov; 8(16):6860-6870. PubMed ID: 31560165
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ibrutinib versus temsirolimus: 3-year follow-up of patients with previously treated mantle cell lymphoma from the phase 3, international, randomized, open-label RAY study.
    Rule S; Jurczak W; Jerkeman M; Rusconi C; Trneny M; Offner F; Caballero D; Joao C; Witzens-Harig M; Hess G; Bence-Bruckler I; Cho SG; Thieblemont C; Zhou W; Henninger T; Goldberg J; Vermeulen J; Dreyling M
    Leukemia; 2018 Aug; 32(8):1799-1803. PubMed ID: 29572505
    [No Abstract]   [Full Text] [Related]  

  • 11. Ibrutinib: a review of its use in patients with mantle cell lymphoma or chronic lymphocytic leukaemia.
    Kim ES; Dhillon S
    Drugs; 2015 May; 75(7):769-76. PubMed ID: 25802231
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Observational study of lenalidomide in patients with mantle cell lymphoma who relapsed/progressed after or were refractory/intolerant to ibrutinib (MCL-004).
    Wang M; Schuster SJ; Phillips T; Lossos IS; Goy A; Rule S; Hamadani M; Ghosh N; Reeder CB; Barnett E; Bravo MC; Martin P
    J Hematol Oncol; 2017 Nov; 10(1):171. PubMed ID: 29096668
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase 1 trial of copanlisib plus ibrutinib in relapsed/refractory mantle cell lymphoma.
    Qualls D; Lam HY; Whiting K; Kumar A; Matasar M; Owens C; Nichols C; Espeleta JA; Qiu A; Subzwari S; Biggar E; Seshan V; Salles G; Younes A; Batlevi C
    Blood Adv; 2022 Sep; 6(18):5262-5266. PubMed ID: 35171976
    [No Abstract]   [Full Text] [Related]  

  • 14. Efficacy and safety of ibrutinib in Japanese patients with relapsed or refractory mantle cell lymphoma.
    Maruyama D; Nagai H; Fukuhara N; Kitano T; Ishikawa T; Shibayama H; Choi I; Hatake K; Uchida T; Nishikori M; Kinoshita T; Matsuno Y; Nishikawa T; Takahara S; Tobinai K
    Cancer Sci; 2016 Dec; 107(12):1785-1790. PubMed ID: 27616553
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CDKN1C-mediated growth inhibition by an EZH1/2 dual inhibitor overcomes resistance of mantle cell lymphoma to ibrutinib.
    Kagiyama Y; Fujita S; Shima Y; Yamagata K; Katsumoto T; Nakagawa M; Honma D; Adachi N; Araki K; Kato A; Inaki K; Ono Y; Fukuhara S; Kobayashi Y; Tobinai K; Kitabayashi I
    Cancer Sci; 2021 Jun; 112(6):2314-2324. PubMed ID: 33792119
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ibrutinib With Rituximab in First-Line Treatment of Older Patients With Mantle Cell Lymphoma.
    Jain P; Zhao S; Lee HJ; Hill HA; Ok CY; Kanagal-Shamanna R; Hagemeister FB; Fowler N; Fayad L; Yao Y; Liu Y; Moghrabi OB; Navsaria L; Feng L; Nogueras Gonzalez GM; Xu G; Thirumurthi S; Santos D; Iliescu C; Tang G; Medeiros LJ; Vega F; Avellaneda M; Badillo M; Flowers CR; Wang L; Wang ML
    J Clin Oncol; 2022 Jan; 40(2):202-212. PubMed ID: 34797699
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Four-year follow-up of a single arm, phase II clinical trial of ibrutinib with rituximab (IR) in patients with relapsed/refractory mantle cell lymphoma (MCL).
    Jain P; Romaguera J; Srour SA; Lee HJ; Hagemeister F; Westin J; Fayad L; Samaniego F; Badillo M; Zhang L; Nastoupil L; Kanagal-Shamanna R; Fowler N; Wang ML
    Br J Haematol; 2018 Aug; 182(3):404-411. PubMed ID: 29785709
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term outcomes and mutation profiling of patients with mantle cell lymphoma (MCL) who discontinued ibrutinib.
    Jain P; Kanagal-Shamanna R; Zhang S; Ahmed M; Ghorab A; Zhang L; Ok CY; Li S; Hagemeister F; Zeng D; Gong T; Chen W; Badillo M; Nomie K; Fayad L; Medeiros LJ; Neelapu S; Fowler N; Romaguera J; Champlin R; Wang L; Wang ML
    Br J Haematol; 2018 Nov; 183(4):578-587. PubMed ID: 30175400
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Outcomes for Recurrent Mantle Cell Lymphoma Post-Ibrutinib Therapy: A Retrospective Cohort Study from a Japanese Administrative Database.
    Rai S; Tanizawa Y; Cai Z; Huang YJ; Taipale K; Tajimi M
    Adv Ther; 2022 Oct; 39(10):4792-4807. PubMed ID: 35984628
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Whole genome copy number analysis in search of new prognostic biomarkers in first line treatment of mantle cell lymphoma. A study by the LYSA group.
    Le Bris Y; Magrangeas F; Moreau A; Chiron D; Guérin-Charbonnel C; Theisen O; Pichon O; Canioni D; Burroni B; Maisonneuve H; Thieblemont C; Oberic L; Gyan E; Pellat-Deceunynck C; Hermine O; Delfau-Larue MH; Tessoulin B; Béné MC; Minvielle S; Le Gouill S
    Hematol Oncol; 2020 Oct; 38(4):446-455. PubMed ID: 32472610
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.